VCNX (Vaccinex) Growth Rank: 2 (As of Jul. 23, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCNX Vaccinex Inc VCNX
50 GF Score
Price $1.18
View Full Analysis

What is Vaccinex Growth Rank?

Vaccinex VCNX 50 Growth Rank is 2 as of Jul. 23, 2026, which is at its 10-year median of 2.00. GuruFocus rates VCNX with a GF Score™ of 50/100.

Vaccinex has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

VCNX vs SXTP, PHGE, CPMV: Growth Rank Comparison

For the Biotechnology subindustry, Vaccinex's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaccinex Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's Growth Rank distribution charts can be found below:

* The bar in red indicates where Vaccinex's Growth Rank falls into.


VCNX
50GF Score
Vaccinex Inc VCNX
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Vaccinex (VCNX) has a Growth Rank of 2 as of Jul. 23, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Vaccinex and its competitors. This is near median its historical median of 2.00. Over the past decade, Vaccinex's Growth Rank has ranged from 1.00 to 4.00.
Is Vaccinex's Growth Rank too high?
Vaccinex's current Growth Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 4.00. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's Growth Rank compare to SXTP and PHGE?
Vaccinex's Growth Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Vaccinex's own Growth Rank has ranged from 1.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Vaccinex and its competitors. Vaccinex's current Growth Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current Growth Rank of 2. The current Growth Rank is 2, which is near median its 10-year median of 2.00. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Vaccinex (VCNX), the current Growth Rank is 2 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaccinex Business Description

Address 1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score

Get the complete analysis for VCNX

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price